Marianna Rachmiel1,2, Pnina Strauss3, Nitzan Dror4, Hadassa Benzaquen4, Orit Horesh4, Nave Tov3, Naomi Weintrob2,5, Zohar Landau2,6, Michal Ben-Ami7, Alon Haim8,9, Moshe Phillip2,4, Tzvi Bistritzer1,2, Eli C Lewis9, Yael Lebenthal2,4. 1. Pediatric Diabetes Service, Assaf Harofeh Medical Center, Zerifin, Israel. 2. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. 3. Kamada Ltd, Ness-Ziona, Israel. 4. The Jesse Z. and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center, Petah-Tikva, Israel. 5. Pediatric Endocrinology and Diabetes Unit, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. 6. Pediatric Endocrine and Diabetes Unit, E. Wolfson Medical Center, Holon, Israel. 7. Pediatric Endocrine and Diabetes Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat-Gan, Israel. 8. Pediatric Diabetes Unit, Soroka Medical Center, Beer-Sheva, Israel. 9. Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Abstract
BACKGROUND AND OBJECTIVES:Alpha-1 antitrypsin (AAT) has been shown to reduce pro-inflammatory markers and protect pancreatic islets from autoimmune responses in recent studies. Our aim was to evaluate its safety and tolerability in three different doses, in a pediatric population with recent onset type 1 diabetes mellitus (T1DM). METHODS: A 37-wk prospective, open-label, phase I/II interventional trial, comprised of 24 recently diagnosed subjects (12 males; age 12.9 ± 2.4 yr), who received 18 infusions of 40, 60, or 80 mg/kg/dose high-purity, liquid, ready to use AAT over 28 wk (Glassia(®) ; Kamada Ltd., Ness Ziona, Israel). PRIMARY OUTCOMES: safety and tolerability; secondary outcomes: glycemic control, C-peptide reserve, and autoantibody levels. Possible responders were defined as individuals with peak C-peptide that declined less than 7.5% below baseline. RESULTS: No serious adverse events, diabetic ketoacidosis (DKA), or severe hypoglycemic episodes were reported. Adverse events were dose-independent and transient. Glycemic control parameters improved during the study in all groups, independent of dosage. Hemoglobin A1c (HbA1c) decreased from 8.43 to 7.09% (mean, p < 0.001). At the end of the study, 18 subjects (75%) had a peak C-peptide ≥0.2 pmol/mL. Eight subjects (33.3%) were considered possible responders and were characterized by shorter duration of T1DM at screening (54.5 ± 34.3 vs. 95.9 ± 45.7 d, p = 0.036) and greater decrease in their HbA1c during the study period (-2.94 ± 1.55 vs.-0.95 ± 1.83%, p = 0.016). CONCLUSIONS:AAT treatment was safe and well tolerated in pediatric subjects with recently diagnosed autoimmune diabetes. Placebo-controlled studies with larger cohorts and dose range are warranted in order to assess efficacy in maintaining pancreatic beta cell reserve and glycemic control.
RCT Entities:
BACKGROUND AND OBJECTIVES:Alpha-1 antitrypsin (AAT) has been shown to reduce pro-inflammatory markers and protect pancreatic islets from autoimmune responses in recent studies. Our aim was to evaluate its safety and tolerability in three different doses, in a pediatric population with recent onset type 1 diabetes mellitus (T1DM). METHODS: A 37-wk prospective, open-label, phase I/II interventional trial, comprised of 24 recently diagnosed subjects (12 males; age 12.9 ± 2.4 yr), who received 18 infusions of 40, 60, or 80 mg/kg/dose high-purity, liquid, ready to use AAT over 28 wk (Glassia(®) ; Kamada Ltd., Ness Ziona, Israel). PRIMARY OUTCOMES: safety and tolerability; secondary outcomes: glycemic control, C-peptide reserve, and autoantibody levels. Possible responders were defined as individuals with peak C-peptide that declined less than 7.5% below baseline. RESULTS: No serious adverse events, diabetic ketoacidosis (DKA), or severe hypoglycemic episodes were reported. Adverse events were dose-independent and transient. Glycemic control parameters improved during the study in all groups, independent of dosage. Hemoglobin A1c (HbA1c) decreased from 8.43 to 7.09% (mean, p < 0.001). At the end of the study, 18 subjects (75%) had a peak C-peptide ≥0.2 pmol/mL. Eight subjects (33.3%) were considered possible responders and were characterized by shorter duration of T1DM at screening (54.5 ± 34.3 vs. 95.9 ± 45.7 d, p = 0.036) and greater decrease in their HbA1c during the study period (-2.94 ± 1.55 vs.-0.95 ± 1.83%, p = 0.016). CONCLUSIONS:AAT treatment was safe and well tolerated in pediatric subjects with recently diagnosed autoimmune diabetes. Placebo-controlled studies with larger cohorts and dose range are warranted in order to assess efficacy in maintaining pancreatic beta cell reserve and glycemic control.
Authors: Srinu Tumpara; Beatriz Martinez-Delgado; Gema Gomez-Mariano; Bin Liu; David S DeLuca; Elena Korenbaum; Danny Jonigk; Frank Jugert; Florian M Wurm; Maria J Wurm; Tobias Welte; Sabina Janciauskiene Journal: Front Pharmacol Date: 2020-07-03 Impact factor: 5.810
Authors: Gordon C Weir; Mario R Ehlers; Kristina M Harris; Sai Kanaparthi; Alice Long; Deborah Phippard; Lia J Weiner; Brett Jepson; James G McNamara; Maria Koulmanda; Terry B Strom Journal: Pediatr Diabetes Date: 2018-05-07 Impact factor: 4.866
Authors: Boris M Baranovski; Eyal Ozeri; Galit Shahaf; David E Ochayon; Ronen Schuster; Nofar Bahar; Noa Kalay; Pablo Cal; Mark I Mizrahi; Omer Nisim; Pnina Strauss; Eran Schenker; Eli C Lewis Journal: J Pharmacol Exp Ther Date: 2016-11-07 Impact factor: 4.030
Authors: Nuria Maicas; Johan van der Vlag; Janin Bublitz; Sandrine Florquin; Marinka Bakker-van Bebber; Charles A Dinarello; Vivienne Verweij; Roos Masereeuw; Leo A Joosten; Luuk B Hilbrands Journal: PLoS One Date: 2017-02-24 Impact factor: 3.240
Authors: Friedrich Mittermayer; Erica Caveney; Claudia De Oliveira; G Alexander Fleming; Loukas Gourgiotis; Mala Puri; Li-Jung Tai; J Rick Turner Journal: Curr Diabetes Rev Date: 2017